Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.93 CAD | +1.02% | +2.77% | +14.26% |
03-22 | Knight Therapeutics Price Target Raised to $7 at RBC | MT |
03-21 | Knight Therapeutics Reports Fourth Quarter Results | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.26% | 434M | |
+6.97% | 71.94B | |
-10.86% | 5.13B | |
+46.43% | 4.66B | |
+5.38% | 3.97B | |
-16.20% | 2.55B | |
+21.10% | 2.41B | |
-26.20% | 2.36B | |
+19.92% | 2.21B | |
+8.36% | 1.71B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Brief: Entering into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree (viloxazine) in Canada